SPRY Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

Total Revenue: $32.5 million, with U.S. net product revenue for Nephi at $31.3 million, a 2.5-fold increase from Q2 and exceeding consensus expectations of $28.3 million.
Operating Expenses: R&D expenses were $2.8 million; SG&A expenses were $74.8 million due to investments in marketing and direct-to-consumer (DTC) campaigns.
Net Loss: $51.2 million or $0.52 per share.
Cash Position: Ended Q3 with $288 million in cash, cash equivalents, and short-term investments, following a $250 million term loan facility secured in September.

2. Strategic Updates and Business Highlights

Nephi Growth: Strong quarter-over-quarter growth driven by increased patient starts and demand. Positive real-world treatment outcomes were highlighted, with 90% of patients effectively treated with a single dose.
Get Nephi On Us Program: Launched to facilitate hassle-free virtual prescribing, aimed at increasing patient adoption and reducing barriers for healthcare providers (HCPs).
International Expansion: Nephi launched in Germany and received approval in Japan, with anticipated launches in Canada and China by 2026.
Market Share: Growth in new prescribers and overall patient engagement, with 19% of new prescriptions coming from previously lapsed patients.

3. Forward Guidance and Outlook

Q4 Expectations: Anticipated decline in sales from Q3 due to seasonality in the epinephrine market, with expectations for continued market share growth.
2026 Outlook: Confidence in returning to quarter-over-quarter growth as market share and prescription volumes rise, supported by the new Get Nephi On Us program and international launches.

4. Bad News, Challenges, or Points of Concern

Market Dynamics: Temporary pause in market share growth during the back-to-school season due to increased patient visits limiting HCPs' ability to discuss new treatments.
Prior Authorization (PA) Requirements: Approximately 50% of covered lives require some form of PA, which poses a barrier to access.
IQVIA Data Limitations: Concerns regarding the accuracy of IQVIA data in reflecting Nephi’s true market performance, as it does not capture all sales channels.

5. Notable Q&A Insights

Performance vs. Expectations: Management indicated that Q3 results met internal expectations despite challenges faced in the summer.
Institutional Sales: Management is beginning formal marketing efforts to boost institutional sales, though specific volume details were not disclosed due to inconsistency.
Impact of Virtual Program: Positive feedback from HCPs about the Get Nephi On Us program, which aims to simplify the prescribing process and reduce patient dropout rates.
Payer Engagement: Ongoing discussions with major payers (e.g., CVS Caremark) regarding formulary inclusion and potential removal of PA requirements, with optimism for progress in early 2026.

Overall, ARS Pharmaceuticals demonstrated significant growth in Q3 2025, driven by strategic initiatives and a strong cash position, while also facing challenges related to market dynamics and access barriers.

SPRY — ARS Pharmaceuticals, Inc.